VERACODE
28.7.2022 08:52:11 CEST | Business Wire | Press release
Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform in Europe. Companies can now secure their software across the entire software development lifecycle (SDLC) with the added capabilities of dynamic analysis and API scanning, complementing Veracode’s static analysis, software composition analysis and manual penetration testing tools. The Veracode European Region , a cloud-based instance, allows customer data to stay resident in the EU to meet policy requirements for cloud computing.
Demand for a SaaS-based software security solution that supports data residency has never been greater. With a 20x increase * in security scanning cadence over the past decade, organisations are now testing apps for flaws more thoroughly than ever. Many are shifting further left and combining static, dynamic, and software composition analysis to gain a comprehensive view of risk and compliance to policies.
Veracode’s EMEA Chief Technology Officer, John Smith, said, “The European market has a growing need to consolidate and automate application security, while meeting stringent data residency requirements. The options for achieving this at scale are limited and complex: on-premise solutions require a large, upfront investment and frequent upgrades, while other SaaS platforms are often a pared-down version of existing on-premise products. Veracode’s cloud-native platform helps customers keep costs down and increase efficiencies by integrating multiple software security tools into one easy-to-use solution that also monitors policy compliance.”
Based in Frankfurt, Germany, the Veracode European Region is a cloud-based instance that offers customers in EMEA a broad suite of solutions as part of its unified Continuous Software Security Platform, which bridges the gap between security and development teams. Dynamic analysis and API scanning are the latest capabilities to be made available in the market. The integrated platform is unique since it gives customers a “single pane of glass” view of security posture across their entire SDLC.
Seamlessly embedded into the environments where developers work, Veracode creates a frictionless experience for developers to code securely without compromising speed of delivery. This is paramount to help businesses keep pace with accelerating deployment times, as well as to provide a comprehensive view of risk, remediation guidance, peer benchmarking, and rich analytics throughout the development pipeline.
Powered by nearly two decades of aggregate data, the cloud-native platform continually finetunes itself to improve accuracy, yielding impressively low false-positive rates. It also streamlines workflows by running daily updates of the vulnerability database, so customers are immediately apprised of any potential threats.
A customer of Veracode, a European commerce body, said, “The privacy and protection of our customers is our highest priority, so we need to be confident in our software security programme. Veracode gives us this assurance with a fully SaaS platform that is resident in the EU. Initially, we needed an automated dynamic analysis product that could crawl our applications at scale but wanted to avoid the pain of amassing several disparate tools over time. With Veracode, we are safe in the knowledge that we can leverage multiple solutions in one place as we continue to shift security further left.”
Find out more about Veracode’s European Region here .
*Veracode State of Software Security Report v12, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com , on the Veracode blog and on Twitter .
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005607/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
